001     136766
005     20240321220131.0
024 7 _ |a 10.1073/pnas.1218667110
|2 doi
024 7 _ |a pmid:23267072
|2 pmid
024 7 _ |a pmc:PMC3545757
|2 pmc
024 7 _ |a 0027-8424
|2 ISSN
024 7 _ |a 1091-6490
|2 ISSN
024 7 _ |a altmetric:1269820
|2 altmetric
037 _ _ |a DZNE-2020-03088
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a Bock, Fabian
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc.
260 _ _ |a Washington, DC
|c 2013
|b National Acad. of Sciences
264 _ 1 |3 online
|2 Crossref
|b Proceedings of the National Academy of Sciences
|c 2012-12-24
264 _ 1 |3 print
|2 Crossref
|b Proceedings of the National Academy of Sciences
|c 2013-01-08
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1586257869_6464
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The coagulation protease activated protein C (aPC) confers cytoprotective effects in various in vitro and in vivo disease models, including diabetic nephropathy. The nephroprotective effect may be related to antioxidant effects of aPC. However, the mechanism through which aPC may convey these antioxidant effects and the functional relevance of these properties remain unknown. Here, we show that endogenous and exogenous aPC prevents glomerular accumulation of oxidative stress markers and of the redox-regulating protein p66(Shc) in experimental diabetic nephropathy. These effects were predominately observed in podocytes. In vitro, aPC inhibited glucose-induced expression of p66(Shc) mRNA and protein in podocytes (via PAR-1 and PAR-3) and various endothelial cell lines, but not in glomerular endothelial cells. Treatment with aPC reversed glucose-induced hypomethylation and hyperacetylation of the p66(Shc) promoter in podocytes. The hyperacetylating agent sodium butyrate abolished the suppressive effect of aPC on p66(Shc) expression both in vitro and in vivo. Moreover, sodium butyrate abolished the beneficial effects of aPC in experimental diabetic nephropathy. Inhibition of p66(Shc) expression and mitochondrial translocation by aPC normalized mitochondrial ROS production and the mitochondrial membrane potential in glucose-treated podocytes. Genetic ablation of p66(Shc) compensated for the loss of protein C activation in vivo, normalizing markers of diabetic nephropathy and oxidative stress. These studies identify a unique mechanism underlying the cytoprotective effect of aPC. Activated PC epigenetically controls expression of the redox-regulating protein p66(Shc), thus linking the extracellular protease aPC to mitochondrial function in diabetic nephropathy.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Butyrates
|2 NLM Chemicals
650 _ 7 |a DNA Primers
|2 NLM Chemicals
650 _ 7 |a Protein C
|2 NLM Chemicals
650 _ 7 |a Shc Signaling Adaptor Proteins
|2 NLM Chemicals
650 _ 7 |a Shc1 protein, mouse
|2 NLM Chemicals
650 _ 7 |a Src Homology 2 Domain-Containing, Transforming Protein 1
|2 NLM Chemicals
650 _ 2 |a Analysis of Variance
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Butyrates: pharmacology
|2 MeSH
650 _ 2 |a Chromatin Immunoprecipitation
|2 MeSH
650 _ 2 |a DNA Methylation: drug effects
|2 MeSH
650 _ 2 |a DNA Primers: genetics
|2 MeSH
650 _ 2 |a Diabetes Mellitus, Experimental: complications
|2 MeSH
650 _ 2 |a Diabetic Nephropathies: drug therapy
|2 MeSH
650 _ 2 |a Diabetic Nephropathies: etiology
|2 MeSH
650 _ 2 |a Epigenetic Repression: drug effects
|2 MeSH
650 _ 2 |a Gene Knockdown Techniques
|2 MeSH
650 _ 2 |a Immunoblotting
|2 MeSH
650 _ 2 |a Immunohistochemistry
|2 MeSH
650 _ 2 |a Membrane Potential, Mitochondrial: drug effects
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Mitochondria: drug effects
|2 MeSH
650 _ 2 |a Mitochondria: metabolism
|2 MeSH
650 _ 2 |a Podocytes: metabolism
|2 MeSH
650 _ 2 |a Protein C: pharmacology
|2 MeSH
650 _ 2 |a Reverse Transcriptase Polymerase Chain Reaction
|2 MeSH
650 _ 2 |a Shc Signaling Adaptor Proteins: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Shc Signaling Adaptor Proteins: metabolism
|2 MeSH
650 _ 2 |a Src Homology 2 Domain-Containing, Transforming Protein 1
|2 MeSH
650 _ 2 |a Statistics, Nonparametric
|2 MeSH
650 _ 2 |a Subcellular Fractions
|2 MeSH
700 1 _ |a Shahzad, Khurrum
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Wang, Hongjie
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Stoyanov, Stoyan
|0 P:(DE-2719)2809920
|b 3
|u dzne
700 1 _ |a Wolter, Juliane
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Dong, Wei
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Pelicci, Pier Giuseppe
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Kashif, Muhammed
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Ranjan, Satish
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Schmidt, Simone
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Ritzel, Robert
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Schwenger, Vedat
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Reymann, Klaus G
|0 P:(DE-2719)2740485
|b 12
|u dzne
700 1 _ |a Esmon, Charles T
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Madhusudhan, Thati
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Nawroth, Peter P
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Isermann, Berend
|0 P:(DE-HGF)0
|b 16
|e Corresponding author
773 1 8 |a 10.1073/pnas.1218667110
|b : Proceedings of the National Academy of Sciences, 2012-12-24
|n 2
|p 648-653
|3 journal-article
|2 Crossref
|t Proceedings of the National Academy of Sciences
|v 110
|y 2012
|x 0027-8424
773 _ _ |a 10.1073/pnas.1218667110
|g Vol. 110, no. 2, p. 648 - 653
|0 PERI:(DE-600)1461794-8
|n 2
|q 110:2<648 - 653
|p 648-653
|t Proceedings of the National Academy of Sciences of the United States of America
|v 110
|y 2012
|x 0027-8424
856 7 _ |2 Pubmed Central
|u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545757
909 C O |o oai:pub.dzne.de:136766
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2809920
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2740485
913 1 _ |a DE-HGF
|b Forschungsbereich Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|2 G:(DE-HGF)POF3-300
|v Disease Mechanisms and Model Systems
|x 0
914 1 _ |y 2013
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b P NATL ACAD SCI USA : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b P NATL ACAD SCI USA : 2017
920 1 _ |0 I:(DE-2719)1310007
|k AG Dityatev
|l Molecular Neuroplasticity
|x 0
920 1 _ |0 I:(DE-2719)1310005
|k AG Reymann
|l Pathophysiology of Dementia
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1310007
980 _ _ |a I:(DE-2719)1310005
980 _ _ |a UNRESTRICTED
999 C 5 |a 10.1007/s12185-012-1059-0
|9 -- missing cx lookup --
|2 Crossref
|o 10.1007/s12185-012-1059-0
999 C 5 |a 10.1126/science.1071699
|9 -- missing cx lookup --
|2 Crossref
|o 10.1126/science.1071699
999 C 5 |a 10.1074/jbc.C100017200
|9 -- missing cx lookup --
|2 Crossref
|o 10.1074/jbc.C100017200
999 C 5 |a 10.1172/JCI38476
|9 -- missing cx lookup --
|2 Crossref
|o 10.1172/JCI38476
999 C 5 |a 10.1016/j.thromres.2004.09.011
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.thromres.2004.09.011
999 C 5 |a 10.1111/j.1538-7836.2012.04621.x
|9 -- missing cx lookup --
|2 Crossref
|o 10.1111/j.1538-7836.2012.04621.x
999 C 5 |a 10.1038/nm1667
|9 -- missing cx lookup --
|2 Crossref
|o 10.1038/nm1667
999 C 5 |a 10.1038/414813a
|9 -- missing cx lookup --
|2 Crossref
|o 10.1038/414813a
999 C 5 |a 10.2337/db08-0057
|9 -- missing cx lookup --
|2 Crossref
|o 10.2337/db08-0057
999 C 5 |a 10.1016/j.cellsig.2012.01.008
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.cellsig.2012.01.008
999 C 5 |y 2009
|2 Crossref
|o 2009
999 C 5 |a 10.1074/jbc.M401844200
|9 -- missing cx lookup --
|2 Crossref
|o 10.1074/jbc.M401844200
999 C 5 |a 10.1016/j.cell.2005.05.011
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.cell.2005.05.011
999 C 5 |a 10.1074/jbc.M200280200
|9 -- missing cx lookup --
|2 Crossref
|o 10.1074/jbc.M200280200
999 C 5 |a 10.1161/CIRCRESAHA.112.266593
|9 -- missing cx lookup --
|2 Crossref
|o 10.1161/CIRCRESAHA.112.266593
999 C 5 |a 10.2337/db05-1477
|9 -- missing cx lookup --
|2 Crossref
|o 10.2337/db05-1477
999 C 5 |a 10.1182/blood-2011-07-365973
|9 -- missing cx lookup --
|2 Crossref
|o 10.1182/blood-2011-07-365973
999 C 5 |a 10.1093/hmg/ddh131
|9 -- missing cx lookup --
|2 Crossref
|o 10.1093/hmg/ddh131
999 C 5 |a 10.1046/j.1365-2141.2000.02128.x
|9 -- missing cx lookup --
|2 Crossref
|o 10.1046/j.1365-2141.2000.02128.x
999 C 5 |a 10.1096/fj.09-138743
|9 -- missing cx lookup --
|2 Crossref
|o 10.1096/fj.09-138743
999 C 5 |a 10.1161/01.RES.0000255691.76142.4a
|9 -- missing cx lookup --
|2 Crossref
|o 10.1161/01.RES.0000255691.76142.4a
999 C 5 |a 10.2337/diabetes.55.01.06.db05-0894
|9 -- missing cx lookup --
|2 Crossref
|o 10.2337/diabetes.55.01.06.db05-0894
999 C 5 |a 10.1074/jbc.M109.008482
|9 -- missing cx lookup --
|2 Crossref
|o 10.1074/jbc.M109.008482
999 C 5 |a 10.1152/ajpcell.00563.2009
|9 -- missing cx lookup --
|2 Crossref
|o 10.1152/ajpcell.00563.2009
999 C 5 |a 10.1073/pnas.0609656104
|9 -- missing cx lookup --
|2 Crossref
|o 10.1073/pnas.0609656104
999 C 5 |a 10.1111/j.1460-9568.2011.07972.x
|9 -- missing cx lookup --
|2 Crossref
|o 10.1111/j.1460-9568.2011.07972.x
999 C 5 |a 10.1007/s00125-007-0728-7
|9 -- missing cx lookup --
|2 Crossref
|o 10.1007/s00125-007-0728-7
999 C 5 |a 10.1016/j.jnutbio.2007.01.010
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.jnutbio.2007.01.010
999 C 5 |a 10.1073/pnas.1107140108
|9 -- missing cx lookup --
|2 Crossref
|o 10.1073/pnas.1107140108


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21